Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22, 2025

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.

BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars

April 21, 2025

Biosimilar and Biologic Use Increasing in Greek Patients With IBD

April 19, 2025

The Top 5 Biosimilar Articles for the Week of April 14

April 18, 2025

Trastuzumab Biosimilar Adoption Increased in Japan Due to Reimbursement

April 17, 2025

Featured Content

President Trump Signs Executive Order to Bring Down Drug Prices

April 16th 2025

By Skylar Jeremias

Article

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.

How State Substitution Laws Shape Insulin Biosimilar Adoption

April 15th 2025

By Skylar Jeremias

Article

States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.

Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

April 14th 2025

By Skylar Jeremias

Article

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.

The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD

April 13th 2025

By Cameron Santoro

Video

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

Experts Pressure Congress to Remove Roadblocks for Biosimilars

April 12th 2025

By Skylar Jeremias

Article

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.

The Top 5 Biosimilar Articles for the Week of April 7

April 11th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 7, 2025.

FDA Approves Biocon Biologics' Bevacizumab Biosimilar

April 10th 2025

By Skylar Jeremias

Article

Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).

Teva and Samsung Bioepis Launch Biosimilar Epysqli

April 9th 2025

By Skylar Jeremias

Article

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for patients with rare, life-threatening hematologic conditions.

BioRationality: Commemorating the 15th Anniversary of the BPCIA

April 8th 2025

By Sarfaraz K. Niazi, PhD

Article

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.

Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers

April 7th 2025

By Skylar Jeremias

Article

Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.